BRAUN
11.5.2021 09:02:07 CEST | Business Wire | Press release
Braun celebrates its 100th anniversary in 2021 and we are pleased to announce the 21st BraunPrize International Design Competition, with a virtual awards ceremony due to take place in October 2021.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210511005118/en/
Established in 1968, the BraunPrize was Germany’s first international competition with the aim to promote the work of young designers. Braun’s continuous commitment to this cause has been highly regarded by the design world and the design-aware public ever since.
This year, young, up-and-coming designers and inventors will be tasked with exploring good design to address and solve the challenges of today and tomorrow; and Braun’s commitment to nurturing young talent will see this year’s total prize value increase to $100,000 USD.
A recent global study, conducted by Braun of 18-25 year olds, revealed that Gen Z believes that good design will play a pivotal role in its future. In fact, 4 out of 5 (78%) agreed that accessibility—regardless of age, impairments or skill level—and ease of use are the single most important areas in which design can deliver an impactful change. Simple and useful design means good design for everyone—design that anyone can understand and anyone can make use of to better their life and to better our collective future.
Braun has shaped the past, present and future with ‘good design’. Braun believes that good design follows the principles of ‘Simple, Useful and Built to last,’ and that these design tenents remain as relevant in 2021 as they were in 1921 in making life better for people and the environment. Braun knows that the next 100 years will be shaped through the power of ‘good design’ for our collective benefit, so the 2021 BraunPrize International Design Competition will challenge creative minds to help shape tomorrow.
Oliver Grabes, Head of Braun Design and Chairman of the BraunPrize commented:
“The 2021 BraunPrize International Design Competition challenge is an opportunity for young designers, inventors and students to identify design ideas and visionary concepts that will help promote behavioral change and make an impact on today’s society and the future of our planet. Design that can effect this type of positive social impact is good design at its best.
Oliver continued: “We are really excited by this year’s competition and encourage you to help us shape tomorrow. 2018 saw more submissions than ever, with 3,087 entrants from 107 counties, making it a record year for the BraunPrize. We can’t wait to see what the 2021 BraunPrize International Design Competiton will unearth.”
For more information, please visit www.uk.braun.com/en-gb/braunprize or on Instagram @braunprize.
THE 2021 BRAUN PRIZE INTERNATIONAL DESIGN COMPETITION DETAILS
THE 2021 CHALLENGE: SHAPE TOMORROW
A call to action to help shape tomorrow. A forum for young designers, inventors and students with a commitment to exploring good design to address and solve the challenges of today and tomorrow.
WHO IS ELIGIBLE
The 2021 BraunPrize International Design Competition is open globally and is free to enter. Submissions are welcome from young designers and inventors with less than 5 years work experience and students of any profession.
PRIZE MONEY
The BraunPrize International Design Competition will award $100,000 USD in prize money.
JURY PANEL
The 2021 BraunPrize Internation Design Competition Jury Panel will comprise of international design leaders from across the globe.
SUBMISSION
Submissions for the 2021 BraunPrize International Design Competition will open in July 2021 and the BraunPrize Winner announcements will take place in October 2021.
NOTES TO EDITORS
- The BraunPrize was established in 1968
- The BraunPrize 2021 marks the 21st edition of the international design competition
- In 2018, the BraunPrize received 3,087 entries from 107 countries
- The BraunPrize 2021 is organized by Braun, a Procter & Gamble brand, and managed by the Braun Design Team in Kronberg, Germany
- Braun, a subsidiary of Procter & Gamble founded in Germany in 1921, develops and manufactures a wide variety of small domestic appliances that marry technical innovation, reliable quality and distinctive design. These range from electric shavers and beauty products to hair care appliances. Braun products enjoy worldwide distribution. Please visit www.braun.com for the latest news and in-depth information about the Braun brand.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005118/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom